Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Keratosis, Actinic 5Lymphoma, T-Cell, Cutaneous 2Vascular Malformations 1Uterine Cervical Dysplasia 1Surgical Wound Infection 1Pilonidal Sinus 1Pancreatic Neoplasms 1Pain 1Mycosis Fungoides 1Keratosis 1High-grade Anal Intraepithelial Neoplasia 1Hemangioma, Capillary 1Hemangioma 1Head and Neck Neoplasms 1Dermatitis, Contact 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Cancer Lymphedema 1

Interventions

Carboplatin 784Pemetrexed 607Cisplatin 545Paclitaxel 491pembrolizumab 464Docetaxel 440Gemcitabine 328Erlotinib Hydrochloride 307Radiotherapy 258Nivolumab 244Bevacizumab 233osimertinib 178Drug Therapy 164durvalumab 157atezolizumab 135Gefitinib 134Radiosurgery 133Vinorelbine 111Cetuximab 97130-nm albumin-bound paclitaxel 94Ipilimumab 86Magnetic Resonance Spectroscopy 84Taxes 79Surgical Procedures, Operative 74Afatinib 68Albumin-Bound Paclitaxel 66Specimen Handling 61Etoposide 61Cyclophosphamide 60tislelizumab 59

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Non-Small-Cell Lung × Ointments × Clear all
NCT01593995 2014-11-04

EGF Ointment for Erlotinib Skin Lesion

Dong-A University Hospital

Phase 2 Completed
52 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡